Carderock Capital Management Has Cut Ansys (ANSS) Holding; Idera Pharmaceuticals (IDRA)’s Sentiment Is 1.46

November 15, 2017 - By Adrian Erickson

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The company has market cap of $397.54 million. The Firm utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor targeting technology and third-generation antisense (3GA) technology. It currently has negative earnings. Using TLR technology, the Company creates synthetic oligonucleotide drug candidates to act by modulating the activity of specific TLRs.

Carderock Capital Management Inc decreased Ansys (ANSS) stake by 15.54% reported in 2017Q2 SEC filing. Carderock Capital Management Inc sold 5,781 shares as Ansys (ANSS)’s stock rose 21.87%. The Carderock Capital Management Inc holds 31,427 shares with $3.82 million value, down from 37,208 last quarter. Ansys now has $12.67 billion valuation. The stock declined 0.08% or $0.12 reaching $149.31 per share. About 5,828 shares traded. ANSYS, Inc. (NASDAQ:ANSS) has risen 43.75% since November 15, 2016 and is uptrending. It has outperformed by 27.05% the S&P500.

Analysts await ANSYS, Inc. (NASDAQ:ANSS) to report earnings on February, 28. They expect $0.94 earnings per share, up 2.17% or $0.02 from last year’s $0.92 per share. ANSS’s profit will be $79.77M for 39.71 P/E if the $0.94 EPS becomes a reality. After $0.88 actual earnings per share reported by ANSYS, Inc. for the previous quarter, Wall Street now forecasts 6.82% EPS growth.

Among 15 analysts covering Ansys Inc. (NASDAQ:ANSS), 2 have Buy rating, 2 Sell and 11 Hold. Therefore 13% are positive. Ansys Inc. had 33 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was initiated by Needham with “Hold” on Tuesday, November 22. The rating was initiated by KeyBanc Capital Markets with “Sector Weight” on Thursday, October 8. The firm has “Hold” rating given on Wednesday, September 27 by KeyBanc Capital Markets. The firm has “Hold” rating given on Monday, July 17 by Goldman Sachs. The firm has “Hold” rating given on Friday, September 22 by Citigroup. Robert W. Baird maintained ANSYS, Inc. (NASDAQ:ANSS) rating on Monday, August 28. Robert W. Baird has “Buy” rating and $130.0 target. The stock has “Hold” rating by Evercore on Wednesday, August 2. The firm earned “Neutral” rating on Friday, November 3 by Citigroup. Pacific Crest initiated ANSYS, Inc. (NASDAQ:ANSS) on Thursday, October 8 with “Equal Weight” rating. RBC Capital Markets maintained ANSYS, Inc. (NASDAQ:ANSS) on Thursday, August 3 with “Hold” rating.

Since May 23, 2017, it had 0 buys, and 2 sales for $842,960 activity. 2,000 shares were sold by ZILVITIS PATRICK J, worth $248,000. THURK MICHAEL sold $594,960 worth of ANSYS, Inc. (NASDAQ:ANSS) on Thursday, May 25.

Investors sentiment increased to 1.18 in 2017 Q2. Its up 0.28, from 0.9 in 2017Q1. It is positive, as 20 investors sold ANSS shares while 150 reduced holdings. 84 funds opened positions while 117 raised stakes. 80.72 million shares or 1.44% less from 81.90 million shares in 2017Q1 were reported. State Common Retirement Fund reported 0.12% of its portfolio in ANSYS, Inc. (NASDAQ:ANSS). Daiwa Securities has 0% invested in ANSYS, Inc. (NASDAQ:ANSS). Farr Miller & Washington Limited Liability Dc accumulated 3,580 shares. King Luther Cap Mngmt Corporation reported 0% of its portfolio in ANSYS, Inc. (NASDAQ:ANSS). Hanseatic owns 5,725 shares. Dupont Management holds 0% or 1,226 shares. Bamco Ny has 2.62 million shares for 1.63% of their portfolio. Natixis owns 0.01% invested in ANSYS, Inc. (NASDAQ:ANSS) for 9,426 shares. Ent reported 26 shares or 0% of all its holdings. Creative Planning owns 875 shares or 0% of their US portfolio. State Of Wisconsin Investment Board owns 95,504 shares or 0.04% of their US portfolio. Schwab Charles Investment Mgmt invested in 0.05% or 425,386 shares. Kentucky Retirement Insur Fund reported 0.05% stake. Commerzbank Aktiengesellschaft Fi, Germany-based fund reported 2,886 shares. Cibc Inc accumulated 3,636 shares.

About 71,735 shares traded. Idera Pharmaceuticals Inc (IDRA) has risen 21.13% since November 15, 2016 and is uptrending. It has outperformed by 4.43% the S&P500.

Broadfin Capital Llc holds 0.81% of its portfolio in Idera Pharmaceuticals Inc for 3.85 million shares. Baker Bros. Advisors Lp owns 10.29 million shares or 0.15% of their US portfolio. Moreover, Mycio Wealth Partners Llc has 0.07% invested in the company for 246,527 shares. The France-based Natixis has invested 0.06% in the stock. Hollencrest Securities Llc, a California-based fund reported 177,570 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :